From: Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis
Characteristics | ||
---|---|---|
Age (years) at diagnosis (median, IQR) | Median | IQR |
5.6 | 3.6–9.3 | |
N | % | |
Gender | ||
Male | 177 | 28.1 |
Female | 454 | 71.9 |
Ethnicity | ||
Hispanic | 95 | 15.1 |
Race | ||
Caucasian | 519 | 82.3 |
African-American | 82 | 13 |
JDM Category | ||
Amyopathic | 9 | 1.4 |
Probable | 490 | 77.7 |
Definite | 48 | 7.6 |
Missing | 84 | 13.3 |
History of Calcinosis | 84 | 13.3 |
History of biologic use | 242 | 38.4 |
IVIG | 225 | 35.7 |
Rituximab | 26 | 4.1 |
Anti-TNFa | 35 | 5.6 |
Certolizumab | 0 | 0 |
Etanercept | 22 | 3.5 |
Golimumab | 1 | 0.2 |
Adalimumab | 7 | 1.1 |
Infliximab | 13 | 2 |
Abatacept | 3 | 0.48 |
Anti-IL1b | 2 | 0.32 |
High glucocorticoid exposurec (n = 572) | 316 | 50 |